Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant gemcitabine + docetaxel followed by doxorubicin versus observation for uterus-limited high-grade uterine leiomyosarcoma
NL-OMON41992Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, docetaxel and doxorubicin in uterine leiomyosarcoma (uLMS) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Planned start Nov 2014; status: withdrawn.
02
Drugs
gemcitabinedocetaxeldoxorubicin
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NL-OMON41992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41992.